ArticleLeukemia2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
Inga Hund, Maria Elena Hess, Geoffroy Andrieux, Julia Stomper, Gabriele Greve, Christoph Niemöller, Tobias Ma, David Uhl, Olga Grishina, Felicitas Thol and 9 more
Abstract read
In one paragraphArticle in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Inga HundDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-5389-9481 Julia StomperDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-3858-4385 Gabriele GreveDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Christoph NiemöllerDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Tobias MaDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0009-0009-1258-8976 David UhlDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Olga GrishinaClinical Trials Unit, Medical Center-University of Freiburg, Freiburg, Germany.
Martina CrysandtDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
Justus DuysterDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-7325-7753 Melanie BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-3670-0602 Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-1186-1650 Heiko BeckerDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. heiko.becker@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0002-6919-4048 Funding
Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) EkoEstMed-FKZ 01ZZ2015Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) NanodiagBW P3Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) PM4Onco-FKZ 01ZZ2322ADeutsche Forschungsgemeinschaft (German Research Foundation) FOR 2674 A02Deutsche Forschungsgemeinschaft (German Research Foundation) FOR 2674 A05 BE 6461/1-2Deutsche Forschungsgemeinschaft (German Research Foundation) LU 429/16-2José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) 17 R/2019José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) AH06-01
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID41057684
PMCPMC12589117
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390